F-652 Recruiting Phase 2 Trials for Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04498377Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19